Neutropenia

Neutropenia

The Neutropenia market is expected to register a CAGR of approx. 5.5% over the period of 2023-2030. The Neutropenia is a medical condition characterized by a low count of neutrophils; a type of white blood cell essential for the immune system. Neutropenia can result from various causes, including chemotherapy, certain medications, or underlying medical conditions. The market encompasses pharmaceutical interventions, therapeutic approaches, diagnostic tools, and supportive care aimed at addressing neutropenia and improving patient outcomes. The Growing prevalence of neutropenia induced by cancer treatments, particularly chemotherapy is boosting the neutropenia market. Cancer patients often experience neutropenia as a side effect, increasing the demand for therapeutic interventions to manage and prevent associated complications. For instance, according to PAHO, in 2023, Globally, there were an estimated 20 million new cases of cancer and 10 million deaths from cancer. The cancer burden will increase by approximately 60% over the next two decades, further straining health systems, people and communities.

• Based on the type, the market has been categorized into congenital neutropenia, febrile neutropenia, cyclic neutropenia, autoimmune neutropenia and others. Among them, the febrile neutropenia segment is expected to grow at a higher CAGR in the market due to its association with increased vulnerability to infections, especially among individuals undergoing cancer treatments such as chemotherapy. Febrile neutropenia occurs when cancer patients with a low neutrophil count (neutropenia) develop a fever, which is often indicative of an underlying infection. Febrile neutropenia poses a significant risk of severe infections, and if not managed promptly and effectively, it can lead to life-threatening complications.
• Based on the treatment, the market has been categorized into antibiotic therapy, colony-stimulating factor therapy, granulocyte transfusion, and others. Among them, the colony-stimulating factor therapy segment is expected to grow at a higher CAGR in the market. The colony-stimulating factor (CSF) therapy segment is crucial in the Neutropenia market because it plays a key role in managing neutropenia, particularly in cases where the condition is induced by chemotherapy or other medical treatments. Neutropenia is often a side effect of cancer treatments, and CSF therapy helps stimulate the production of neutrophils, a type of white blood cell, to reduce the risk of infections. This segment has witnessed growth due to the increasing prevalence of chemotherapy-induced neutropenia and the need for effective supportive care.
• Based on the end-user, the market has been categorized into Hospitals, Homecare ,Speciality Centres, and Others. Among them, the hospital category is to witness higher adoption of Neutropenia during the forecast period. The rising incidence of cancer and the growing awareness of cancer among the general population has led to an increased number of patients seeking medical attention and Type at hospitals. The hospital segment in the Neutropenia market is considered a crucial and growing component. Hospitals play a central role in the diagnosis, treatment, and management of neutropenia, particularly in severe cases where close monitoring, specialized care, and interventions are necessary. Moreover, Severe neutropenia, especially cases involving febrile neutropenia, may require hospitalization. Hospitals offer inpatient services where patients can receive intensive care, continuous monitoring, and prompt intervention in case of complications.
• For a better understanding of the market adoption of the Neutropenia industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The North America neutropenia market is expected to continue to grow in the coming years, driven by the increasing prevalence of cancer and growing awareness of neutropenia among healthcare professionals and the general population, development of advanced imaging techniques and the rise in treatment option. For instance, in 2020, according to American Cancer Society, Cancer is the second most common cause of death in the US, exceeded only by heart disease. around 609,360 deaths from cancer are expected in the US in 2022, which is about 1,670 deaths per day.
• Some of the major players operating in the market include Pfizer Inc., Novartis AG, AstraZeneca, Teva Pharmaceutical Industries Ltd., Mylan N.V, Sanofi , GSK plc , Merck & Co., Inc, Cipla Inc, Seagen, Inc.